Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02618447 · ClinicalTrials.gov registry record · NA
4D Phase Contrast MR: Hypertrophy in Liver Cancer
A NA study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02618447 is a NA study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT02618447, a NA study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The investigators hypothesize that 4Dimensional Phase Contrast Magnetic Resonance Angiography (4D PC MRA) evaluation of portal venous flow predicts underlying liver function and hypertrophic potential in patients with liver cancer presenting for portal vein embolization (PVE). 4D PC MRA may provide a non-invasive measure of liver function that could help determine which patients could safely and successfully undergo PVE and subsequent resection of tumor. By comparing 4D PC MRA results with invasive catheter measurements the investigators will validate the flow findings. Further regression/correlation analysis with functional measures of the liver (HIDA scans), volumetrics, Doppler flow analysis, histology, and outcomes will help the investigators to determine the ability of 4D PC MRA to predict functional status and hypertrophic potential of the liver prior to PVE and hepatectomy allowing for better patient selection and reduced morbidity/mortality.
Interventions
- DEVICE 4Dimensional Phase Contrast Magnetic Resonance Angiography
- PROCEDURE Portal vein embolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-08-05 |
| Est. Completion | 2016-02-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02618447
The ClinicalTrials.gov registry entry for NCT02618447 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 4Dimensional Phase Contrast Magnetic Resonance Angiography is the first listed.
NCT02618447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02618447 about?
NCT02618447 is a clinical study titled "4D Phase Contrast MR: Hypertrophy in Liver Cancer". The investigators hypothesize that 4Dimensional Phase Contrast Magnetic Resonance Angiography (4D PC MRA) evaluation of portal venous flow predicts underlying liver function and hypertrophic potential in patients with liver cancer presenting for portal vein embolization (PVE). 4D PC MRA may provide ...
What is the current status of trial NCT02618447?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2014-08-05. Estimated completion is 2016-02-04.
What interventions are being tested in trial NCT02618447?
The interventions under investigation include: 4Dimensional Phase Contrast Magnetic Resonance Angiography (DEVICE), Portal vein embolization (PROCEDURE).
Who is sponsoring clinical trial NCT02618447?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.